Kimberly-Clark to buy maker of Tylenol
Digest more
Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings ...
Barchart on MSN
Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here?
Kenvue stock soars as Kimberly-Clark agrees to acquire the consumer health giant. Jim Cramer is positive on KVUE shares ...
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its ...
Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when ...
Kimberly-Clark N/A said on Monday it will acquire Tylenol maker Kenvue KVUE-N +0.91% in a deal valued at about ...
1d
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.
Kimberly-Clark agrees to buy Tylenol maker Kenvue in a cash-and-stock deal valued at about $48.7 billion, including debt.
Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback